The Real Study Behind DeepFen Clarity
We're not asking you to take our word for it. Here's the actual peer-reviewed clinical trial — read it yourself, then see the plain-English breakdown below.
Read the Full Study on Frontiers in Nutrition →
Salter D, Gupta SVB, Sairam B, Gupta AK, Maurya R (2025). A standardized combination of Boswellia serrata and Terminalia chebula extracts to improve cognition in adults with subjective memory complaints: a randomized controlled proof-of-concept study. Frontiers in Nutrition, 12:1695341.
DOI: 10.3389/fnut.2025.1695341 · PMID: 41438191
DOI: 10.3389/fnut.2025.1695341 · PMID: 41438191
Why a "Randomized, Double-Blind" Study Actually Matters
A lot of memory supplements point to tradition, or to a study on a different dose, or a different form of the ingredient. Before we show you any results, here's what makes this one worth trusting: neither the participants nor the researchers knew who was getting the real ingredient and who was getting a placebo until the study ended. That's what "double-blind" means — it stops a study from unconsciously favoring the product being tested. "Randomized" means people were assigned to each group by chance, not picked, so the two groups started out comparable. This is the same design standard used to test prescription medications, not the kind of study most supplements rely on.
The Basics
100 adults, ages 40–65, all with real, self-reported memory concerns
120 days, randomized, double-blind, placebo-controlled
300 mg per day of LN19184 (the standardized Boswellia serrata + Terminalia chebula complex, sold commercially as Nutricog®) vs. placebo
Conducted at two independent research sites in India, approved by two separate ethics committees
Registered with the Clinical Trials Registry of India (CTRI/2020/08/027368)
120 days, randomized, double-blind, placebo-controlled
300 mg per day of LN19184 (the standardized Boswellia serrata + Terminalia chebula complex, sold commercially as Nutricog®) vs. placebo
Conducted at two independent research sites in India, approved by two separate ethics committees
Registered with the Clinical Trials Registry of India (CTRI/2020/08/027368)
Not Just "How Do You Feel?"
Researchers didn't rely on self-reported impressions. They used standardized, validated cognitive tests — the same kind used in clinical and academic memory research:
RAVLT (Rey's Auditory Verbal Learning Test): a well-established verbal memory test measuring recall, learning, and how well the mind resists interference — administered at baseline, and again at days 15, 30, 60, 90, and 120
CANTAB: a computerized cognitive testing battery covering 23 individual tests across processing speed, visual memory, and executive function
Athens Insomnia Scale: a validated 8-item self-assessment for sleep quality
Serum BDNF: blood levels of brain-derived neurotrophic factor, a protein tied to memory and learning, measured at baseline and day 120
Safety was tracked throughout — vital signs, blood work, and adverse events at every visit
RAVLT (Rey's Auditory Verbal Learning Test): a well-established verbal memory test measuring recall, learning, and how well the mind resists interference — administered at baseline, and again at days 15, 30, 60, 90, and 120
CANTAB: a computerized cognitive testing battery covering 23 individual tests across processing speed, visual memory, and executive function
Athens Insomnia Scale: a validated 8-item self-assessment for sleep quality
Serum BDNF: blood levels of brain-derived neurotrophic factor, a protein tied to memory and learning, measured at baseline and day 120
Safety was tracked throughout — vital signs, blood work, and adverse events at every visit
The Results, Outcome by Outcome
Memory & Recall (RAVLT)
The LN19184 group showed significant improvement over placebo starting as early as Day 15 for recognition and proactive interference. Delayed recall, total learning, and learning rate were significantly better than placebo by Day 60. Immediate recall improved significantly by Day 90. By Day 120, every RAVLT measure tracked was significantly better than placebo.
Visual Memory & Processing (CANTAB)
Of the 23 individual CANTAB cognitive tests, 16 showed a significant benefit — spanning processing speed, visual memory, and learning. The remaining tests trended in the same direction without reaching statistical significance, which is typical in a study of this size and duration.
Sleep Quality
Insomnia scores improved significantly more in the supplemented group than placebo, with a significant between-group difference from Day 60 onward.
BDNF (the biological marker)
This is the standout number: serum BDNF rose 99.9% in the LN19184 group by Day 120 — compared to 8.5% in the placebo group. BDNF is directly involved in the brain's ability to form and strengthen memory-related connections.
Safety
Only 5 minor, self-limiting side effects were reported across the entire 100-person study (2 in the treatment group: bloating and itching), with no serious adverse events and no clinically significant changes in blood work or vital signs.
The LN19184 group showed significant improvement over placebo starting as early as Day 15 for recognition and proactive interference. Delayed recall, total learning, and learning rate were significantly better than placebo by Day 60. Immediate recall improved significantly by Day 90. By Day 120, every RAVLT measure tracked was significantly better than placebo.
Visual Memory & Processing (CANTAB)
Of the 23 individual CANTAB cognitive tests, 16 showed a significant benefit — spanning processing speed, visual memory, and learning. The remaining tests trended in the same direction without reaching statistical significance, which is typical in a study of this size and duration.
Sleep Quality
Insomnia scores improved significantly more in the supplemented group than placebo, with a significant between-group difference from Day 60 onward.
BDNF (the biological marker)
This is the standout number: serum BDNF rose 99.9% in the LN19184 group by Day 120 — compared to 8.5% in the placebo group. BDNF is directly involved in the brain's ability to form and strengthen memory-related connections.
Safety
Only 5 minor, self-limiting side effects were reported across the entire 100-person study (2 in the treatment group: bloating and itching), with no serious adverse events and no clinically significant changes in blood work or vital signs.
Full Transparency on Funding
This study was funded by Laila Nutra Private Limited, the manufacturer of the standardized ingredient tested (LN19184/Nutricog®). Lead author Dawna Salter is employed by PLT Health Solutions, which commercializes the ingredient.
We're not going to pretend that doesn't matter — it does, and we think you deserve to know it plainly rather than have it buried in a footnote. What we'd point you to instead: this is a registered, peer-reviewed, randomized, double-blind, placebo-controlled trial published in an indexed journal, not a customer survey or an internal white paper. The funding relationship is disclosed in the published paper itself, exactly as the journal requires.
We're not going to pretend that doesn't matter — it does, and we think you deserve to know it plainly rather than have it buried in a footnote. What we'd point you to instead: this is a registered, peer-reviewed, randomized, double-blind, placebo-controlled trial published in an indexed journal, not a customer survey or an internal white paper. The funding relationship is disclosed in the published paper itself, exactly as the journal requires.
Same Dose, Same Ingredient
DeepFen Clarity delivers 300 mg per day of the exact standardized ingredient (LN19184/Nutricog®) used in this trial — split across 2 capsules. One clarification worth being upfront about: the study tested this specific ingredient at this specific dose. It did not test the finished DeepFen Clarity capsule itself as a whole product. That's a distinction we think matters, and one a lot of supplement brands don't bother making.
Frequently Asked Questions
Is this a real, peer-reviewed study?
Yes. It was published in Frontiers in Nutrition, an indexed, peer-reviewed journal, and is publicly searchable on PubMed (PMID: 41438191).
Was DeepFen Clarity itself tested, or just the ingredient?
The ingredient — LN19184/Nutricog®, at 300 mg/day — was tested in this trial. DeepFen Clarity contains that exact same ingredient at that exact same dose.
How is this different from most "clinically studied" supplement claims?
Most brands cite the tradition behind an ingredient, or a study using a different dose or a different form. This is the exact standardized extract, at the exact dose in your bottle, tested in a randomized, double-blind, placebo-controlled trial — the gold standard of clinical research.
Who paid for the study?
The ingredient manufacturer, Laila Nutra Private Limited. This is disclosed in the published paper, as required by the journal.